| Schedule of Segment Reporting Information, by Segment |
The following tables summarize, for the periods indicated, operating results by reportable segment: Cost of goods sold is directly related to product sales only. Revenues derived from co-promote revenue, which made up all of the Dermatology Product Sales in the first quarter had no cost of goods sold. As a result, cost of goods sold was only recorded in the three months ended September 30, 2016. | | | Dermatology | | Pharmaceutical and | | | | | | | | ($ in thousands) | | Products | | Biotechnology Product | | | | | | | | Three Months Ended September 30, 2016 | | Sales | | Development | | National | | Consolidated | | | Net Revenue | | $ | 429 | | $ | 546 | | $ | - | | $ | 975 | | | Direct cost of goods | | | (41) | | | - | | | - | | | (41) | | | Sales and marketing costs | | | (1,244) | | | - | | | - | | | (1,244) | | | Research and development | | | - | | | (8,316) | | | - | | | (8,316) | | | General and administrative | | | (422) | | | (7,198) | | | - | | | (7,620) | | | Segment loss from operations | | $ | (1,278) | | $ | (14,968) | | $ | - | | $ | (16,246) | | | Segment assets | | $ | 2,657 | | $ | 103,225 | | $ | 39,539 | | $ | 145,421 | | | | | Dermatology | | Pharmaceutical and | | | | | | ($ in thousands) | | Products | | Biotechnology Product | | | | | | Three Months Ended September 30, 2015 | | Sales | | Development | | Consolidated | | | Net Revenue | | $ | - | | $ | 25 | | $ | 25 | | | Sales and marketing costs | | | (950) | | | - | | | (950) | | | Research and development | | | - | | | (10,968) | | | (10,968) | | | General and administrative | | | (516) | | | (5,663) | | | (6,179) | | | Segment loss from operations | | $ | (1,466) | | $ | (16,606) | | $ | (18,072) | | | Segment assets | | $ | 1,593 | | $ | 85,271 | | $ | 86,864 | | | | | Dermatology | | Pharmaceutical and | | | | | | | | ($ in thousands) | | Products | | Biotechnology | | | | | | | | Nine Months Ended September 30, 2016 | | Sales | | Product Development | | National | | Consolidated | | | Net Revenue | | $ | 1,793 | | $ | 2,072 | | $ | - | | $ | 3,865 | | | Direct cost of goods | | | (365) | | | - | | | - | | | (365) | | | Sales and marketing costs | | | (4,212) | | | - | | | - | | | (4,212) | | | Research and development | | | - | | | (24,559) | | | - | | | (24,559) | | | General and administrative | | | (1,338) | | | (19,864) | | | - | | | (21,202) | | | Segment loss from operations | | $ | (4,122) | | $ | (42,351) | | $ | - | | $ | (46,473) | | | Segment assets | | $ | 2,657 | | $ | 103,225 | | $ | 39,539 | | $ | 145,421 | | | | | Dermatology | | Pharmaceutical and | | | | | | ($ in thousands) | | Products | | Biotechnology Product | | | | | | Nine Months Ended September 30, 2015 | | Sales | | Development | | Consolidated | | | Net Revenue | | $ | - | | $ | 525 | | $ | 525 | | | Direct cost of goods | | | - | | | - | | $ | - | | | Sales and marketing costs | | | (1,632) | | | - | | | (1,632) | | | Research and development | | | - | | | (24,054) | | | (24,054) | | | General and administrative | | | (1,134) | | | (11,610) | | | (12,744) | | | Segment loss from operations | | $ | (2,766) | | $ | (35,139) | | $ | (37,905) | | | Segment assets | | $ | 1,593 | | $ | 85,271 | | $ | 86,864 | |
|